41 results about "CXCL9" patented technology

The invention provides a method for evaluating the activity of an agent for treating rhinovirus infection or a symptom thereof, a method of detecting or monitoring rhinovirus infection, and a method of treating rhinovirus infection or a symptom thereof. Various embodiments comprise measuring expression of (i) one or more genes selected from the group consisting of CRY2, B3GAT3, C10ORF95, and BATF3, and (ii) one or more genes selected from the group consisting of RNFT2, BTG4, PSD3, CAPN9, SULT1E1, HEY1, LRRC36, RAB3B, ALDH3B1, FAM134B, FAS, PLSCR1, CLEC2B, HAS2, MX1, SP110, GBP1, IFIT3, IFIT1, CXCL9, CXCL10, and CXCL11, from at least one biological sample to produce a gene expression profile, and comparing the gene expression profile to a reference gene expression profile. Systems, computer readable media, compositions, and methods for maintaining or improving respiratory health also are provided.

The invention provides methods for predicting the efficacy of anti-TNF and anti-IL-17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level LIF, CXCL1, CXCL2, CXCL4, CXCL5, CXCL8, CXCL9, CXCL10, CCL2, CCL23, IL-1β, IL-1Ra, TNF, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IFNγ, CXCR1, CXCR4, CXCR5, GM-CSF, GM-CSFR, G-CSF, G-CSFR protein or nucleic acid, or a homolog, portion or derivative thereof markers in a sample derived from the subject.

The invention discloses an application of a scoring system based on an immunogene pair in prediction of immunotherapy curative effect and prognosis of a non-small cell lung cancer patient. The scoring system disclosed by the invention is carried out based on the following four immune related gene pairs: CCL2 and VEGFA genes, CDK1 and CXCL9 genes, HLA-DOB and LCK genes, and IL-12A and TBX21 genes. The IRGP index (IRGPI) calculated based on an immune gene pair scoring system constructed by the invention is significantly related to the progression-free lifetime of a non-small cell lung cancer patient receiving anti-PD-1 immunotherapy. Therefore, the four immune-related gene pairs and the scoring system constructed according to the four immune-related gene pairs can be used for performing curative effect and prognosis prediction on the non-small cell lung cancer patient receiving anti-PD-1 immunotherapy.

The invention relates to a method for acquiring information on a condition of a patient with interstitial pneumonia and application thereof. The present invention addresses the problem of providing ameans capable of identifying the condition of a patient suffering from interstitial pneumonia. The method comprises steps of measuring at least one biomarker in a biological sample of an interstitialpneumonia patient, the biomarker including at least one selected from CXCL9 and CXCL10, a measurement result of the biomarker serving as an index for discrimination between IPAF and CTD-ILD.

The invention provides immunotherapy for targeted transportation of a chemotactic factor and a cytokine via a mesenchymal stem cell. Specifically, the invention provides the mesenchymal stem cell. Themesenchymal stem cell expresses an immunostimulatory factor, wherein the immunostimulatory factor is selected from the group consisting of CCL3, CCL19, CCL21, XCL1, CXCL9, OX40L, 4-1BBL, GITRL, CD40L, and combinations of the above immunostimulatory factors. The mesenchymal stem cell disclosed by the invention can specifically attract and activate immune cells for killing tumor tissues at a tumorpart, and the mesenchymal stem cell and chemotactic factor and / or cytokine have a synergistic effect, so the mesenchymal stem cell has an immune curative effect which is more efficient and low in sideeffect and is remarkably enhanced in tumor tissue killing capability, especially colorectal cancer cell killing capability.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The invention is based, at least in part, on the discovery that an immune-score expression level based on one or more of PD-L1, CXCL9, IFNG, GZMB, CD8A, and PD-1 in a sample obtained from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)).

The invention discloses an application of an Interferon Regulating Factor 1 (IRF1) in regulating and controlling the immunomodulatory effect of human placenta, amnion and umbilical cord derived mesenchymal stem cells. The immunomodulatory effect is the effect of inhibiting T cell proliferation. The biological characteristics of human amniotic membrane, placenta and umbilical cord derived mesenchymal stem cells are researched by utilizing a single cell sequencing technology, and the IRF1 is found to be highly expressed in the placenta, amniotic membrane and umbilical cord derived mesenchymal stem cells in an inflammatory microenvironment. Transcription factor analysis and in-vitro experimental research further prove that the IRF1 can regulate and control the expression of MSC immunosuppressive molecules IDO1, CD274 and STAT1 and chemotactic factors CXCL9 and CXCL10, and in-vitro T cell proliferation experiments find that the IRF1 can regulate and control the T cell proliferation inhibition effect of the umbilical cord MSC, so that an important theoretical basis and a therapeutic target are provided for treatment of autoimmune diseases.

The invention provides a method for evaluating the activity of an agent for treating rhinovirus infection or a symptom thereof, a method of detecting or monitoring rhinovirus infection, and a method of treating rhinovirus infection or a symptom thereof. Various embodiments comprise measuring expression of (i) one or more genes selected from the group consisting of CRY2, B3GAT3, C10ORF95, and BATF3, and (ii) one or more genes selected from the group consisting of RNFT2, BTG4, PSD3, CAPN9, SULT1E1, HEY1, LRRC36, RAB3B, ALDH3B1, FAM134B, FAS, PLSCR1, CLEC2B, HAS2, MX1, SP110, GBP1, IFIT3, IFIT1, CXCL9, CXCL10, and CXCL11, from at least one biological sample to produce a gene expression profile, and comparing the gene expression profile to a reference gene expression profile. Systems, computer readable media, compositions, and methods for maintaining or improving respiratory health also are provided.

The invention relates to a screening method of a tumor immunotherapy prognosis marker. The screening method comprises the following steps: acquiring expression data, mutation data and clinical curative effect data of a candidate gene group of cancer species to be analyzed; performing statistical independence test on the mutation condition of the candidate gene group and the expression condition ofan immune genome, finding out gene mutation related to the immune genome, and sorting genes in the candidate gene group according to association degrees from high to low, wherein the immune genome comprises CD8A, GZMA, GZMB, IFN [gamma], EOMES, CXCL9, CXCL10, and TBX21; dividing the first N genes into a mutation group and a non-mutation group according to whether the first N genes are mutated ornot, performing survival analysis, and selecting M genes with most significant differences for reservation according to log-rank changes; validating the resulting genes in independent datasets to determine mutation and prognostic correlation thereof.

Methods and compositions for treating hemophagocytic lymphohistiocytosis (HLH) are provided. The disclosure also relates generally to methods and compositions for diagnosing and treating disorders associated with elevated levels of CXCL9, elevated levels of total IFNγ, and other biomarkers. The disclosure also relates to methods of treating, delaying the progression of, or otherwise ameliorating a symptom of a disorder in patients with elevated levels of CXCL9 elevated levels of total IFNγ, and other biomarkers using agents that interfere with or otherwise antagonize interferon gamma (IFNγ) signaling, including neutralizing anti-IFNγ antibodies.

The present invention provides a method for predicting the treatment response to anti-cancer immunotherapy of a mammalian cancer patient, the method comprising: a) measuring the gene expression of atleast 2 the following cancer promoting genes: PTGS2, VEGFA, CCL2, IL8, CXCL2, CXCL1, CSF3, IL6, IL1B and IL1A in a sample obtained from the tumour of the patient; b)measuring the gene expression of atleast 2 of the following cancer inhibitory genes: CXCL11, CXCL10, CXCL9, CCL5, TBX21, EOMES, CD8B, CD8A, PRF1, GZMB, GZMA, STAT1, IFNG, IL12B and IL12A in a sample obtained fromthetumour of the patient; c) computing a ratio of the gene expression of said at least 2 cancer promoting genes and the gene expression of said at least 2 cancer inhibitory genes; and d) making a prediction of the treatment response and / or prognosis of the patient based on the gene expression ratio computed in step c). Also provided are related methods for stratifying patients and for treating patients, including withimmune checkpoint blockade therapy.

The invention discloses a kit for detection or assisted detection of tuberculous pleurisy. The kit comprises a device for detecting the expression amount of an immune factor, wherein the immune factor comprises (1) IL-6, IL-13, G-CSF, CCL1, CCL21, IP-10 (CXCL10), CCL8 (MCP-2), CXCL9 (MIG) and CXCL12 (SDF-1); or (2) at least one of IL-6, IL-13, G-CSF, CCL1, CCL21, IP-10 (CXCL10), CCL8 (MCP-2), CXCL9 (MIG) and CXCL12 (SDF-1). Experiments prove that a method for specifically identifying tuberculous pleurisy by taking hydrothorax as a detection object, utilizing a group of immunologic molecular marker, and adopting a multiple-factor microsphere detection technique is developed, and the purposes of improving the disease diagnosis accuracy rate, scientifically judging the state of illness and the like are realized by a multiple-factor combination manner.

The present invention provides methods for selecting patients as having a solid tumor (e.g., bladder cancer, ovarian cancer, colorectal cancer, head and neck cancer, cervical cancer, renal cell carcinoma, and non-small cell lung cancer (NSCLC)) that is responsive to treatment with an anti-PD-L1 antibody, and methods of treating such patients. The method involves detecting expression of an IFNG polynucleotide and / or one or more of polynucleotide markers: CXCL9, CD274, and LAG3, in a biological sample of the patient.

The invention relates to the field of biotechnology, and specifically discloses a method for realizing soluble expression of recombinant CXCL9 protein in Escherichia coli by using fusion expression of a solubilization tag and an intein (Intein) and an application thereof. In the method, the target protein is fused and expressed with a solubilizing tag and an Intein with self-cleavage function, so as to realize the soluble expression and shear release of the target protein. Compared with the known method for expressing recombinant CXCL9 protein in Escherichia coli, the method of the present invention can avoid the denaturation and renaturation process of inclusion bodies, does not need to introduce protease, and can obtain a target product with a completely natural sequence, which is useful for large-scale industrial production Very good application prospects.